ReBoost Nasal Spray Lawsuit Update: Injuries, Recall Status, and Legal Options

On December 16, 2025, MediNatura expanded the recall to all ReBoost lots within expiry and separately included ClearLife Allergy Nasal Spray. The U.S. Food and Drug Administration (FDA) published warnings about potentially life-threatening infections, particularly among immunocompromised consumers.

FDA subsequently classified the ReBoost recall as Class I, its most serious risk category. Although MediNatura reported no adverse events when announcing the expansion, consumers who developed documented infections after using the product may have potential legal claims.

Quick Facts

• Product: ReBoost Nasal Spray, 0.68 fl. oz. (20 mL), distributed by MediNatura New Mexico Inc.
• Recall: Initially announced December 10, 2025, and expanded December 16, 2025.
• Hazard: Yeast, mold, and Achromobacter contamination that could cause serious infections.
• FDA classification: Class I, recall D-0288-2026, covering all lots within expiry.

Latest News on the ReBoost Nasal Spray Recall

November 2026

A November 13, 2026 review of the FDA’s original announcement confirms that MediNatura recalled ReBoost lot 224268 after identifying yeast, mold, and Achromobacter contamination. The affected lot had a December 2027 expiration date [1].

The review also verified the FDA’s December 16 expansion to all ReBoost lots within expiry, alongside a separate ClearLife recall. The manufacturer reported no adverse events associated with the recall at that time [2].

FDA’s openFDA enforcement record, last updated November 4, 2026, identifies ReBoost recall D-0288-2026 as Class I with a recorded status of “Ongoing.” The record confirms nationwide distribution and all lots within expiry [3].

These checks establish the published recall history and recorded enforcement status. They do not establish current injury totals, whether individual refunds are being processed, or the outcome of any lawsuit.

January 2026

The FDA enforcement record lists January 14, 2026, as its report date and January 15, 2026, as the Class I classification date. Class I indicates a reasonable probability of serious adverse health consequences or death.

The classification reflects the potential danger of microbial contamination. It does not establish that deaths or serious infections actually occurred among ReBoost users.

December 2025

On December 16, MediNatura expanded its ReBoost recall following additional investigation. The company also recalled ClearLife Allergy Nasal Spray because of microbial contamination potentially linked to Achromobacter.

The original December 10 announcement had involved only ReBoost lot 224268. On December 12, the Hawaii Department of Health issued a public warning describing the contaminated product, relevant identification codes, and possible infection symptoms [4].

Event	Month/Year	Type	Status	Source	Notes
FDA enforcement record review	November 2026	Regulatory verification	Reviewed	[3]	Class I and recorded status verified
FDA Class I classification	January 2026	Enforcement classification	Class I	[3]	Recall D-0288-2026
Expanded nationwide recall	December 2025	Product recall	Announced	[2]	All ReBoost lots within expiry
Hawaii health advisory	December 2025	Public health warning	Published	[4]	Symptoms and distribution identified
Original ReBoost recall	December 2025	Product recall	Announced	[1]	Lot 224268 initially affected

What Is the ReBoost Nasal Spray Recall?

The recall involves ReBoost Nasal Spray distributed by MediNatura New Mexico Inc. of Albuquerque, New Mexico. The product was marketed as a homeopathic nasal spray for temporary relief of congestion, sinus pressure, sneezing, postnasal drip, and related symptoms.

Testing identified microbial contamination exceeding specifications. MediNatura first recalled one lot, then expanded the action to all lots within expiry.

Which ReBoost Nasal Spray Products Are Recalled?

ReBoost was packaged in a 20 mL bottle inside a white-and-yellow carton. The following information identifies the affected product:

• Product: ReBoost Nasal Spray
• Size: 0.68 fl. oz. (20 mL)
• NDC: 62795-4005-9
• UPC: 787647101863
• Original lot: 224268
• Original lot expiration: December 2027
• Expanded scope: All lots within expiry
• FDA recall number: D-0288-2026

The expanded recall is not limited to lot 224268. Consumers should review product identification and expiration information rather than rely exclusively on the original lot number.

What’s the Problem With ReBoost Nasal Spray?

The product contained yeast, mold, and microbial contamination, including Achromobacter, above established specifications. Contaminated nasal spray may introduce microorganisms into the nasal passages and create a risk of infection.

MediNatura warned that exposure could cause life-threatening infections in immunocompromised individuals. The FDA’s Class I designation reflects the seriousness of the potential hazard.

What Is Achromobacter?

Achromobacter is a genus of bacteria found in environments such as soil and water. Certain species can cause opportunistic infections, particularly among people with weakened immune systems or significant underlying illnesses.

Its identification in product testing does not mean every recalled bottle contained the organism or that every user developed an infection.

What Health Risks Are Associated With ReBoost Nasal Spray?

Microbial contamination may cause illness depending on the organisms involved, exposure, and individual health. Potential symptoms and complications include:

• Persistent sinus irritation or inflammation
• Headaches and facial pain or pressure
• Fever or swollen sinuses
• Facial numbness
• Respiratory or bacterial infections
• Hospitalization for serious infections
• Life-threatening complications in vulnerable individuals

These are possible health consequences, not confirmed injuries among ReBoost users. People experiencing concerning symptoms after product use should obtain medical evaluation.

Why Are Immunocompromised Consumers at Greater Risk?

Individuals with weakened immune defenses may have difficulty controlling certain bacterial or fungal infections. People receiving immunosuppressive treatment or managing serious illnesses may face heightened risks.

The recall specifically warned of life-threatening infections in immunocompromised consumers. Medical evaluation is necessary to determine whether any particular illness involved product exposure.

Have Injuries Been Reported From ReBoost Nasal Spray?

MediNatura reported no adverse events associated with the recall in its December 2025 announcements. The notices did not identify confirmed infections, hospitalizations, or deaths caused by ReBoost.

The reviewed FDA records do not establish a cumulative injury count through November 2026. The original absence of reported injuries does not establish that no subsequent injuries occurred.

Where Was ReBoost Nasal Spray Sold?

ReBoost was distributed nationwide through retail stores and internet sales, including MediNatura’s website. Hawaii health officials identified Foodland as one local retail distribution channel.

The recall applies to affected products regardless of where they were purchased.

What Should Consumers Do With Recalled ReBoost Nasal Spray?

MediNatura instructed consumers to stop using recalled ReBoost immediately. Anyone experiencing symptoms potentially associated with use should contact a healthcare provider.

The manufacturer’s original recall instructions provided refund arrangements for qualifying purchases.

How Can Consumers Obtain a ReBoost Nasal Spray Refund?

The December 2025 recall notice directed direct purchasers to email MediNatura and retail purchasers to return affected products to their original stores.

Recall Contact Information

• Company: MediNatura New Mexico Inc.
• Telephone: 800-621-7644
• Email: recall@medinatura.com
• Original hours: Monday–Friday, 8 a.m.–5 p.m. MST

These are historical recall instructions. Consumers should confirm current processing arrangements because published contact information does not guarantee that individual refund requests are presently being fulfilled.

Could MediNatura Be Liable for ReBoost Nasal Spray Injuries?

Product-liability law may permit compensation when evidence establishes that a defective or contaminated product caused an injury. Potential claims may involve manufacturing defects, negligent quality control, or inadequate warnings, depending on state law.

The recall documents a safety problem but does not automatically establish liability. Medical causation, damages, and applicable filing deadlines remain essential considerations.

Who May Be Affected by the ReBoost Recall?

Consumers who purchased or used affected ReBoost nasal spray were potentially exposed to the contamination hazard. Individuals with compromised immune systems may have faced increased health risks.

Those who developed documented infections after use may have additional legal questions beyond the manufacturer’s refund program.

Do I Qualify for a ReBoost Nasal Spray Lawsuit?

The following questions may help determine whether a potential claim warrants legal evaluation:

• Did you use ReBoost Nasal Spray covered by the nationwide recall?
• Did you develop a serious infection or another documented illness afterward?
• Did the condition require medication, hospitalization, or substantial medical treatment?
• Do you have purchase records, packaging, medical records, or relevant laboratory results?

Answering yes does not guarantee eligibility or compensation. An attorney can assess causation, damages, product identification, and filing deadlines.

What Evidence Should Injured Consumers Preserve?

Product identification and medical documentation may be important in evaluating a potential claim. Relevant evidence includes:

• The nasal spray bottle and carton
• Photographs of lot and expiration information
• Purchase receipts or online order history
• Medical records and laboratory results
• Hospitalization and prescription records
• Communications with MediNatura or retailers
• Medical bills and lost-income documentation

Consumers considering litigation may wish to obtain evidence-preservation guidance before discarding relevant materials. Recalled nasal spray should remain out of use.

How Can Consumers Report an Adverse Reaction?

Consumers and healthcare professionals may report suspected adverse reactions or product-quality problems through FDA’s MedWatch program. The FDA’s recall announcements provide reporting instructions and links to the appropriate forms.

Reporting a suspected reaction does not independently prove that ReBoost caused the condition.

What Compensation May Be Available?

Potential damages may include medical expenses, hospitalization costs, future treatment, lost income, pain and suffering, and other legally recognized losses.

Severe infections may require extensive treatment or rehabilitation. Compensation amounts vary by case. Past results do not guarantee future outcomes.

Speak With a ReBoost Nasal Spray Lawyer

If you developed a serious infection after using recalled ReBoost nasal spray, a product-liability attorney can evaluate your medical records, product information, and exposure history. A free case review can help determine whether the evidence and applicable law support a potential injury claim.

How Does a ReBoost Nasal Spray Lawsuit Work?

1. Free case review. An attorney evaluates the product, injury, and supporting records.
2. Investigation. Evidence may include FDA findings, laboratory tests, and medical documentation.
3. Filing. A qualifying claim may be filed under applicable law.
4. Discovery/negotiation. The parties exchange evidence and may discuss settlement.
5. Resolution. The claim may conclude through settlement, dismissal, court ruling, or trial.

Frequently Asked Questions

What is the ReBoost Nasal Spray Lawsuit?

The ReBoost Nasal Spray Lawsuit refers to potential injury claims associated with recalled ReBoost nasal spray. The recall does not establish a filed lawsuit or finding of liability.

Why was ReBoost nasal spray recalled?

MediNatura identified yeast, mold, and Achromobacter contamination exceeding specifications. The company warned that exposure could cause serious infections.

Which ReBoost nasal spray lots were recalled?

The initial recall covered lot 224268, expiring December 2027. The expanded recall covered all lots within expiry.

Is ReBoost a Class I FDA recall?

Yes. FDA’s enforcement record identifies ReBoost recall D-0288-2026 as Class I, its most serious classification. This describes potential health consequences rather than confirmed injuries.

Have injuries been reported from ReBoost?

MediNatura reported no adverse events when announcing the December 2025 recall. The reviewed sources do not establish a current cumulative injury total.

Can I file a ReBoost Nasal Spray Lawsuit?

A consumer with a documented injury may have a potential claim if evidence supports product-related causation and legal liability. Eligibility depends on applicable law, damages, and filing deadlines.

Is there a ReBoost nasal spray settlement?

The cited regulatory records document the recall, not the outcome of any specific lawsuit. Settlement status requires separate court-record verification.

References

1. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medinatura-new-mexico-inc-issues-voluntary-nationwide-recall-reboost-nasal-spray-due-microbial
2. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/medinatura-new-mexico-inc-expands-voluntary-nationwide-recall-reboost-nasal-spray-and-include
3. https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0288-2026%22
4. https://health.hawaii.gov/news/newsroom/doh-alerts-public-about-medinatura-new-mexicos-reboost-nasal-spray-due-to-potential-yeast-mold-and-microbial-contamination/